⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NXTC News
NextCure, Inc. Common Stock
Form 8-K
sec.gov
NXTC
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
globenewswire.com
NXTC
Form 8-K
sec.gov
NXTC
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
globenewswire.com
NXTC
Form 8-K
sec.gov
NXTC
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
globenewswire.com
NXTC
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
globenewswire.com
NXTC
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
globenewswire.com
NXTC
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
globenewswire.com
NXTC
NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
globenewswire.com
NXTC